Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
American Heart Journal, 2018•Elsevier
Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We
evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with
vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in
patients with nonvalvular atrial fibrillation using coronary computed tomography
angiography.
evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with
vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in
patients with nonvalvular atrial fibrillation using coronary computed tomography
angiography.
Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果